Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 4/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4519972 | 0.91 | KCNH2 (0.34) | NOS1NOS3CYP2D6DRD1HTR2A | |
| Trifluoroacetic Acid SCHEMBL4511571 | 0.91 | NOS1 (0.36) | NOS1PTPN1PIK3CACYP2D6DRD1 | |
| SCHEMBL4519079 | 0.91 | NLRP3 (0.38) | PTPN1PIK3CACYP2D6DRD1HTR2A | |
| Trifluoroacetic Acid SCHEMBL4526972 | 0.85 | PTPN1 (0.33) | NOS1PTPN1CYP2D6DRD1HTR2A | |
| SCHEMBL4528751 | 0.81 | DHFR (0.39) | PTPN1PIK3CACYP2D6DRD1HTR2A | |
| SCHEMBL4524484 | 0.79 | PTPN1 (0.52) | PTPN1CYP2D6DHFR | |
| Trifluoroacetic Acid SCHEMBL5499368 | 0.77 | PTPN1 (0.39) | PTPN1NLRP3DHFRKCNH2 | |
| Trifluoroacetic Acid SCHEMBL4525618 | 0.76 | DHFR (0.52) | PTPN1NLRP3DHFR | |
| Trifluoroacetic Acid SCHEMBL4534719 | 0.76 | PTPN1 (0.47) | PTPN1ADORA2ADHFR | |
| Trifluoroacetic Acid SCHEMBL4521116 | 0.76 | PTPN1 (0.48) | PTPN1CYP2D6DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | disclosed |
| EP-1812409-A1 | AMINOQUINAZOLINES COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2007-08-01 | — | — | EP | disclosed |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2006-09-21 | — | — | US | disclosed |
| US-20060128729-A1 | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-06-15 | — | — | US | disclosed |
| WO-2006050843-A1 | AMINOQUINAZOLINES COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | PTPN5, PTPN1, PTPN7 | NOS1 666/4885PTPN1 2/4885PIK3CA 212/4885 |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | PTPN5, PTPN1, PTPN7 | NOS1 666/4885PTPN1 2/4885PIK3CA 212/4885 |
| US-20060128729-A1 | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | HPSE, ENGASE, UGCG | NOS1 1749/4885PTPN1 3318/4885PIK3CA 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.